Raymond James Financial Inc. Takes Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Raymond James Financial Inc. purchased a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 189,364 shares of the specialty pharmaceutical company's stock, valued at approximately $6,847,000. Raymond James Financial Inc. owned approximately 0.34% of Supernus Pharmaceuticals as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in SUPN. Barclays PLC lifted its holdings in shares of Supernus Pharmaceuticals by 88.3% during the third quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company's stock worth $3,393,000 after buying an additional 51,005 shares during the last quarter. Franklin Resources Inc. raised its stake in shares of Supernus Pharmaceuticals by 7.6% in the third quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company's stock valued at $987,000 after purchasing an additional 2,121 shares in the last quarter. Principal Financial Group Inc. raised its stake in shares of Supernus Pharmaceuticals by 5.4% in the third quarter. Principal Financial Group Inc. now owns 285,411 shares of the specialty pharmaceutical company's stock valued at $8,899,000 after purchasing an additional 14,566 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Supernus Pharmaceuticals by 40.6% in the third quarter. JPMorgan Chase & Co. now owns 253,396 shares of the specialty pharmaceutical company's stock valued at $7,901,000 after purchasing an additional 73,118 shares in the last quarter. Finally, Burney Co. grew its holdings in shares of Supernus Pharmaceuticals by 603.4% in the 4th quarter. Burney Co. now owns 83,152 shares of the specialty pharmaceutical company's stock worth $3,007,000 after purchasing an additional 71,331 shares during the last quarter.

Supernus Pharmaceuticals Trading Down 0.7 %

Shares of NASDAQ:SUPN traded down $0.22 during trading on Tuesday, reaching $32.03. 31,741 shares of the stock were exchanged, compared to its average volume of 493,331. Supernus Pharmaceuticals, Inc. has a 12 month low of $25.53 and a 12 month high of $40.28. The firm has a market cap of $1.79 billion, a PE ratio of 30.04 and a beta of 0.90. The stock has a 50-day moving average price of $31.92 and a 200-day moving average price of $35.01.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. StockNews.com raised shares of Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Thursday, April 17th. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $36.00 target price on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th.

Insiders Place Their Bets

In other news, VP Padmanabh P. Bhatt sold 9,477 shares of the company's stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total transaction of $376,236.90. Following the transaction, the vice president now directly owns 10,149 shares of the company's stock, valued at $402,915.30. This represents a 48.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Jonathan Rubin sold 927 shares of the company's stock in a transaction on Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the transaction, the senior vice president now owns 7,853 shares of the company's stock, valued at $307,444.95. This trade represents a 10.56 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 9.30% of the company's stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.